Sabby Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Sabby Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-70,000	Closed	-$1.23M	–	227
2021 Q3	$1.23M	Sell	70,000 -73,496	-51%	-$859K	0.17%	78
2021 Q2	$1.39M	Sell	143,496 -56,073	-28%	-$528K	0.2%	72
2021 Q1	$2.14M	Buy	199,569 +79,573	+66%	+$984K	0.42%	49
2020 Q4	$1.76M	Buy	+119,996	New	+$1.73M	0.34%	37
2020 Q2	–	Sell	-287,906	Closed	-$1.78M	–	139
2020 Q1	$1.16M	Buy	+287,906	New	+$1.09M	0.48%	23
2016 Q2	–	Sell	-14,137	Closed	-$131K	–	353
2016 Q1	$131K	Buy	+14,137	New	+$119K	0.01%	271

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Sabby Management's TRIL Position: Q4 2021 in Review

Sabby Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 70,000 shares — an estimated $1.23M sold.

Sabby Management first reported a position in TRIL in Q1 2016 and held it in 6 quarters. The position peaked at $2.14M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Sabby Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Sabby Management sold 70,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.23M.
Sabby Management first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 6 quarters.
Sabby Management's Trillium Therapeutics Inc. position peaked at $2.14M in Q1 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.